An unexpected N-terminal loop in PD-1 dominates binding by nivolumab
Programmed cell death 1 (PD-1) is a key target for cancer immunotherapy. Here the authors present the crystal structure of the extracellular PD-1 domain with the clinically approved monoclonal antibody nivolumab, which shows that the N-terminal PD-1 loop is crucial for antibody binding.
Guardado en:
Autores principales: | Shuguang Tan, Hao Zhang, Yan Chai, Hao Song, Zhou Tong, Qihui Wang, Jianxun Qi, Gary Wong, Xiaodong Zhu, William J. Liu, Shan Gao, Zhongfu Wang, Yi Shi, Fuquan Yang, George F. Gao, Jinghua Yan |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c5339e61324843929579ea934d9f1b79 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Molecular basis of EphA2 recognition by gHgL from gammaherpesviruses
por: Chao Su, et al.
Publicado: (2020) -
Nivolumab-associated DRESS in a genetic susceptible individual
por: Qian Li, et al.
Publicado: (2021) -
Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Alexander N Shoushtari, et al.
Publicado: (2021) -
A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2
por: Qingrui Huang, et al.
Publicado: (2021) -
Publisher Correction: A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2
por: Qingrui Huang, et al.
Publicado: (2021)